Johnson & Johnson
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson Full-Year Guidance by Quarter
Full-Year Guidance — Estimated reported sales growth midpoint (%) (%)
Johnson & Johnson Full-Year Guidance: 7.4% in Q3 2026, up 1.7 pts from a year earlier.
Latest, Q3 2026
7.4%
Period ended Sep 30, 2026
Change on a year earlier
+1.7 pts
5.7% in Q3 2025
History
17 quarters
Since Q3 2022
Sources
17
Documents cited below
Where the Q3 2026 figure comes from
“|| Estimated Reported Sales 3 / Mid-point Change vs. Prior Year / Mid-point | $101.0B – $101.4B / $101.2B 7.2% – 7.6% / 7.4% | $100.8B – $101.4B / $101.1B 7.0% – 7.6% / 7.3%”
Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Reported in Form 8-K EX-99.1 Full-Year Guidance Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Johnson & Johnson Full-Year Guidance (%), quarterly Q3 2022–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/guid-rep-sales-growth-mid-pct
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.